Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 13

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 13
---
ust stock ownership guidelines for non-employee directors and executive officers |     | •Compensation clawback policy                                                                                     |     | •Anti-hedging and anti-pledging policies                                                      |
| •Limits on board member service on other public company boards                       |     | •Annual say-on-pay vote                                                                                           |     | •Board has significant interaction with senior management and access to other employees       |
| •Majority voting in uncontested director elections, with resignation policy          |     | •No stockholder rights or similar plan                                                                            |     | •Demonstrated commitment to stockholder engagement                                            |
| •Mandatory director retirement age                                                   |     | •Guidance from independent compensation consultant, with compensation decisions made by reference to a peer group |     | •Caps on performance-based cash and equity incentive compensation for our executive officers. |

| Independence                                                                                            
 •Eight out of nine directors are independent                                                            
 •The roles of Board Chair and CEO are separate                                                          |     | Refreshment and Diversity                                                                                                                                            
 •44% of Board members are women and/or ethnically diverse                                                                                                            
 •Commitment to Board refreshment: six new directors appointed in last five years, including a new director in 2024 and Mr. Raha joining the Board on April 30, 2025. |
|:--------------------------------------------------------------------------------------------------------|:----|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •Regular executive sessions of independent directors without management at Board and committee meetings |     | •Annual Board and committee self-assessments, including one-on-one interviews led by the Board Chair                                                                 |
| •Board committees include only independent directors                                                    |     | •NGC regularly assesses the effectiveness of each director                                                                                                           |

#### Executive Compensation Highlights

#### (page 30)
Our compensation programs are designed to attract and retain executive talent, motivate our executive officers through pay-for-performance metrics to enhance our growth and profitability and increase long-term stockholder value. Our fiscal year 2024 executive compensation program emphasizes long-term value creation, as the vast majority of compensation is tied to stock price performance or contingent on achieving rigorous performance targets. Our incentive programs incorporate performance metrics such as revenue, adjusted operating income, adjusted EPS, and relative total stockholder return measured against the Nasdaq Health Care Index ("IXHC"). To further align executive interests with those of stockholders, we have recently adopted enhanced stock ownership requirements and maintained a strong commitment to performance-based equity compensation. Additionally, our compensation framework ensures that annual bonus payments are formula-driven and based on pre-determined objective measures of financial performance.